Ioan Totu

Totus Medicines Announces Appointment of Nassim Usman, Ph.D., as President & CEO and the Closing of a $66M Series B Funding

Retrieved on: 
Freitag, Dezember 15, 2023
Principal, Drug development, MIT, Sirna Therapeutics, Organic chemistry, CSO, Morgenthaler, Culture, McGill University, Series, Therapy, University, Corporate title, Growth, AI, Pharmaceutical industry, Sanofi, Merck, Ioan Totu

"He brings exceptional experience and acumen to a company poised to bring much-needed therapies to market.

Key Points: 
  • "He brings exceptional experience and acumen to a company poised to bring much-needed therapies to market.
  • His strong management experience will help shape Totus as we continue to advance breakthrough therapeutics, and just as importantly, Nassim embodies our culture and values."
  • Before joining Totus Medicines, Dr. Usman served as President, CEO and Board member at Catalyst Biosciences (NASDAQ:CBIO, now Gyre Therapeutics, NASDAQ:GYRE).
  • Proceeds from the Series B financing will be used to advance Totus' clinical program, expand the pipeline, and evolve the platform.

Totus Medicines Appoints John Maraganore to Scientific Advisory Board

Retrieved on: 
Donnerstag, Oktober 19, 2023
Signal transduction, China Executive Leadership Academy in Pudong, Ioan Totu, RNA interference, Therapy, RNA, Alnylam Pharmaceuticals, BIO, PI3K, Disease, Biotechnology Innovation Organization, Drug discovery, Cancer, John Maraganore, Patient, SAB, United States Air Force Scientific Advisory Board, Pharmaceutical industry

EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Totus Medicines , the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board (SAB).

Key Points: 
  • EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Totus Medicines , the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board (SAB).
  • Maraganore brings over three decades of experience and most recently served as the founding CEO and director of Alnylam Pharmaceuticals.
  • Maraganore remains a member of the Alnylam Scientific Advisory Board.
  • "It's an honor to have John Maraganore join as the newest member of our Scientific Advisory Board," said Totus CEO and co-founder Neil Dhawan, Ph.D. "John brings valuable experience in advancing therapeutics from discovery to commercialization at a time when our first program is rapidly advancing through clinical trials.

Cetera Welcomes $327 Million AUA Team to Cetera Advisors

Retrieved on: 
Dienstag, Oktober 10, 2023
Partnership, AUA, Cetera Financial Group, Fox, Financial adviser, Ioan Totu, Johan Bardoul, Cetara

LOS ANGELES, Oct. 10, 2023 /PRNewswire/ -- Cetera Financial Group (Cetera), the premier financial advisor Wealth Hub, announced that Raymond Bardoul** and Brian Fox**, have joined Cetera Advisors via Totus Wealth Management (Totus). Based in metro Atlanta, Ga., the Bardoul and Fox partnership was previously affiliated with MML Investors Services and will launch an Atlanta office for Totus, which affiliated with Cetera in 2021 and has since continuously grown its assets and advisors. Both Fox and Bardoul provide comprehensive financial planning and investment advice to clients and combined have more than $327 million in assets under administration* as of August 23, 2023.

Key Points: 
  • LOS ANGELES, Oct. 10, 2023 /PRNewswire/ -- Cetera Financial Group (Cetera), the premier financial advisor Wealth Hub, announced that Raymond Bardoul** and Brian Fox**, have joined Cetera Advisors via Totus Wealth Management (Totus).
  • "The decision to affiliate with Cetera was made simple by Cetera Advisors and Totus Wealth Management," Bardoul said.
  • "We couldn't be happier with the service we've already received from both Cetera Advisors and Totus," Fox added.
  • In September 2022, Burrows Capital Advisors, a $3 billion AUA team led by industry veteran Don Burrows, joined Totus from Hilltop.

Totus Medicines CEO to Chair Next-Generation Undruggable and Present at Future of R&D Week 2023

Retrieved on: 
Mittwoch, September 27, 2023
Senior, Generator, Innovation, Future, Drug discovery, Culture, Partnership, Disease, Pharmaceutical industry, Pharma, Ioan Totu

Totus Co-founder, CEO, and CSO Neil Dhawan is serving as the Event Chairperson for the first day of the conference, Next-Generation Undruggable and participating throughout the event.

Key Points: 
  • Totus Co-founder, CEO, and CSO Neil Dhawan is serving as the Event Chairperson for the first day of the conference, Next-Generation Undruggable and participating throughout the event.
  • He will also be speaking on the panel 'Evolution Vs Revolution: How Should the Culture around AI be Managed?'
  • Future of R&D Week consists of three events showcasing innovation in the biotech and pharma space, Next Generation Undruggable, AI in Pharma: Discovery and AI in Pharma: Clinical Development.
  • For more information on Next-Generation Undruggable and Future of R&D Week, visit https://www.nextgenerationundruggable.com/ .

Totus Medicines Expands its Scientific Advisory Board with the Addition of Dr. Lewis Cantley, Dr. Hope Rugo, and Dr. Josep Tabernero

Retrieved on: 
Mittwoch, April 12, 2023
SAB, San Francisco Bay Area, Special Program of Assisted Reproduction, AACR, SPORE, Science and technology in Asia, Vall, ESMO, American Society of Clinical Oncology, Cancer, American Association for Cancer Research, United States Air Force Scientific Advisory Board, Research, Oncology, Signal transduction, European Society for Medical Oncology, Cantley, Ioan Totu, AGIO, Harvard Medical School, ASCO, PI3K, United Nations Scientific Committee on the Effects of Atomic Radiation, Cell biology, Patient, UCSF, Drug discovery, Society, Agios Pharmaceuticals, IDeA Networks of Biomedical Research Excellence, Breast cancer, Disease, Pharmaceutical industry, Antibiotics, Medical device

To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.

Key Points: 
  • To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3Kα, using the Totus Accel™ Platform.
  • They include:
    Dr. Lewis Cantley : Dr. Cantley's work has helped define the field of signal transduction, and he notably discovered the PI3K pathway and its role in cancer.
  • "I am excited to join the Scientific Advisory Board of Totus Medicines.
  • The SAB advances Totus' efforts to continue to deliver unparalleled efficiency and accuracy with its groundbreaking drug discovery platform.

Totus Medicines Announces Poster Presentation for TOS-358, the First Highly Selective Covalent Molecule Targeting PI3Kα, at the 34th EORTC-NCI-AACR Symposium in Barcelona

Retrieved on: 
Donnerstag, Oktober 27, 2022
Cancer, San Francisco Bay Area, PI3K, Ioan Totu, PDX, ENA, Cell, Multimedia, Pharmaceutical industry

The poster exhibits data from the clinical development candidate TOS-358, the first highly selective covalent molecule targeting PI3K, which is the most mutated oncogene in cancer.

Key Points: 
  • The poster exhibits data from the clinical development candidate TOS-358, the first highly selective covalent molecule targeting PI3K, which is the most mutated oncogene in cancer.
  • Totus Medicines is set to start clinical trials of TOS-358 in early 2023.
  • Presentation Title:Preclinical characterization of TOS-358, a potent and selective covalent inhibitor of wild-type and mutant PI3K with superior anticancer activity
    TOS-358 is a highly selective covalent inhibitor of PI3K.
  • Founded in 2019, Totus Medicines has developed the next generation of cellular analysis to create life-changing therapies to treat previously untreatable diseases.

Totus Medicines CEO to Present at Next-Generation Undruggable Conference

Retrieved on: 
Dienstag, Oktober 11, 2022
PI3K, Patient, Conference, Multimedia, San Francisco Bay Area, Cancer, EDT, Pharmaceutical industry, Ioan Totu

EMERYVILLE, Calif., Oct. 11, 2022 /PRNewswire/ -- Totus Medicines , the drug discovery company using breakthrough chemical biology to make the total human genome druggable, announced today that Neil Dhawan, Totus CEO and co-founder , will speak at the Next-Generation Undruggable Conference in Boston on October 11 at 11:20 a.m. EDT.

Key Points: 
  • EMERYVILLE, Calif., Oct. 11, 2022 /PRNewswire/ -- Totus Medicines , the drug discovery company using breakthrough chemical biology to make the total human genome druggable, announced today that Neil Dhawan, Totus CEO and co-founder , will speak at the Next-Generation Undruggable Conference in Boston on October 11 at 11:20 a.m. EDT.
  • Dhawan will discuss the power of Totus' comprehensive high-throughput platform and its ability to identify highly specific and potent molecules against previously undruggable targets.
  • He will outline how the Totus platform revealed TOS-358, the first highly selective covalent molecule targeting PI3K, which is the most mutated oncogene in cancer.
  • Founded in 2019, Totus Medicines has developed the next generation of cellular analysis to create life-changing therapies to treat previously untreatable diseases.

Totus Medicines Announces New San Francisco Bay Area Headquarters & Expanded Lab Space

Retrieved on: 
Donnerstag, März 31, 2022
People, Cancer, Colon, Lung, Stomach, San Francisco Bay Area, Data science, Growth, Multimedia, Breast, Research, Computational chemistry, Genome, Machine learning, Gene, Chemistry, PI3K, SAN, Ioan Totu, AI, Pharmaceutical industry

SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Totus Medicines, the drug discovery company harnessing proprietary chemical biology and AI to address previously untreatable cancers, today announced the relocation of its headquarters to Emeryville, California. The company is investing heavily in R&D in the coming months, including hiring for 60+ roles across several disciplines, including data science, machine learning, clinical development, and chemistry.

Key Points: 
  • SAN FRANCISCO, March 31, 2022 /PRNewswire/ -- Totus Medicines, the drug discovery company harnessing proprietary chemical biology and AI to address previously untreatable cancers, today announced the relocation of its headquarters to Emeryville, California.
  • Totus Medicines' platform uses proprietary molecular tags that track drug binding in individual cells to screen billions of drug molecules across thousands of genes in parallel.
  • Totus Medicines' new 35,000-square-foot facility will include office and lab space for the company's research and development efforts.
  • Totus is based in the San Francisco Bay Area.

Totus Medicines Partners with Mila to Advance Drug Discovery Technologies in Mission to Treat the Untreatable

Retrieved on: 
Donnerstag, März 24, 2022
Drug development, LinkedIn, Organization, Therapy, Growth, Multimedia, Drug design, Research, Artificial intelligence, Genome, Knowledge, Twitter, Machine learning, Drug discovery, Efficiency, Ioan Totu, Deep learning, University, Partnership, Medical device, Pharmaceutical industry, AI

CAMBRIDGE, Mass., March 24, 2022 /PRNewswire/ -- Totus Medicines, a drug discovery company using revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases, today announced the start of a collaboration with Mila, the Quebec artificial intelligence (AI) institute, which rallies the largest concentration of academic deep-learning researchers. The AI-focused partnership will enable both organizations to leverage each other's distinct expertise and knowledge for drug discovery. This effort comes at a particularly important time for Totus, as the company is on track to advance a drug candidate into first-in-human clinical trials later this year.

Key Points: 
  • The AI-focused partnership will enable both organizations to leverage each other's distinct expertise and knowledge for drug discovery.
  • This effort comes at a particularly important time for Totus, as the company is on track to advance a drug candidate into first-in-human clinical trials later this year.
  • "Totus' chemical biology expertise, coupled with our AI expertise, has the potential to transform the process of drug discovery as we know it."
  • Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome.

Totus Medicines Hires Corporate Strategy Leader Laura Miller

Retrieved on: 
Mittwoch, März 23, 2022
Business development, Cancer, Colon, COO, Therapy, Lung, Stomach, Clinical trial, Multimedia, CBO, Business, Breast, Biotechnology, Strategic management, Miller, CEO, Hotel manager, Genome, Pfizer, WW, Industry, Mutation, Join, PI3K, Pharmaceutical industry, Genentech, Ioan Totu

CAMBRIDGE, Mass., March 23, 2022 /PRNewswire/ -- Totus Medicines, a drug discovery company using revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases, today announced the hiring of Laura Miller as the company's first Chief Business Officer (CBO)/Chief Operating Officer (COO). Miller will report directly to CEO and co-founder Dr. Neil Dhawan, Ph.D., and help to execute the company's strategy and vision.

Key Points: 
  • Miller joins Totus with over 20 years of business development experience in the biotech and pharma industries.
  • In her new position, she will be responsible for leading corporate strategy efforts, overseeing operations, and developing and transforming the company to meet evolving business needs.
  • Miller comes to Totus from Genentech, where she was most recently Executive Director and Head of Product Development Excellence, Portfolio and Product Development Strategy.
  • Founded in 2019, Totus Medicines uses revolutionary chemical biology to create life-changing therapies to treat previously untreatable diseases across the entire human genome.